Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1691
This examiner grants 0% of resolved cases
Stanley Bram serves as an examiner in Tech Center 1600 and has a minimal track record with only 1 resolved case in Art Unit 1691. This case did not result in an allowance, leading to an allowance rate pct of 0.0. The median days to allowance for this single resolution was 251, which is a relatively short timeframe for a case to reach a final status.
The interview lift pct is 0.0, reflecting a lack of evidence regarding the effectiveness of interviews for this examiner. Because the data is limited to 1 resolved case, it is difficult to draw broad conclusions about his examination style or the difficulty of Art Unit 1691. Practitioners should note the 0.0% allowance rate but also recognize that the 251-day timeline suggests a quick initial resolution. As more cases are resolved, these figures will likely evolve to provide a more comprehensive view of his prosecution profile.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18729768 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Non-Final OA | Vanderbilt University |
| 18593708 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF ALZHEIMER'S DISEASE | Non-Final OA | UNIVERSITY OF SOUTH FLORIDA |
| 18829496 | COMPOSITION FOR ENHANCING SKIN VITALITY CONTAINING A THYMOL ESTER-BASED COMPOUND | Non-Final OA | Amorepacific Corporation |
| 18768434 | AURORA KINASE AND JANUS KINASE INHIBITORS FOR PREVENTION OF GRAFT VERSUS HOST DISEASE | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18783819 | METHODS OF SYNTHESIZING 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL] PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE | Non-Final OA | IMBRIA PHARMACEUTICALS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy